Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial (JapicCTI-205363/NCT04457297). ALTAIR is the circulating tumor DNA (ctDNA)-guided treatment escalation arm of the CIRCULATE-Japan adaptive…
Letter from the CEO of Tivic Health, Jennifer Ernst.
Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today issued the following letter from the CEO, Jennifer Ernst, providing additional information regarding the company’s current report on Form 8-K filed with the…
Global Adult Vaccine Market Projected to Reach $27.65 Billion by 2028 with a Strong CAGR of 6.01% During 2023-2028 – ResearchAndMarkets.com
The global adult vaccine market is expected to witness substantial growth, reaching a projected value of US$ 27.65 Billion by 2028, with a strong compound annual growth rate (CAGR) of 6.01% during 2022-2028. Vaccines play a crucial role in global…
Shapeways Secures Multi-Million-Dollar Medical ContractsRealizing a 3X growth within its medical base in the past 4 years
Shapeways, Inc. (NYSE: SHPW), a global leader in the digital manufacturing industry, announced today the expansion of its medical customer base within its Enterprise Manufacturing Solutions business by securing two significant contracts. These strategic partnerships should generate revenue of approximately $2.5…
Impetus Grants Secures $10 million Commitment from Hevolution Foundation and Rosenkranz Foundation to Fund Aging Science
Impetus Grants, a nonprofit foundation dedicated to funding aging-related research that might otherwise be overlooked by traditional funding sources, announces a new round of matching funding. Hevolution Foundation, a global non-profit organization that provides grants and early-stage investments to incentivize research…
United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma
Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating the development of promising treatments to market announced the FDA authorization of a Phase II clinical trial to re-assess a targeted treatment in light of newly discovered pharmacogenomic predictor data in…
ViroCell Appoints Brian Collins as CFO
ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”). Brian brings a wealth of relevant experience to…
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of James Robinson, former President and Chief Executive Officer (CEO) of Urovant Sciences, to its…
Oak Street Health Opens Tenth Center in Indiana
Oak Street Health, a network of value-based primary care centers for adults on Medicare and the only primary care provider to carry the AARP name, is now welcoming patients at the new Midtown center at 1310 Broadway in Gary, IN. This is the…
DaVita Announces Wendy Schoppert to Join its Board of Directors
DaVita Inc. today announced that its Board of Directors appointed a new independent director, Wendy Schoppert, to join the Board, effective as of July 14, 2023. “We’re pleased to welcome Wendy to DaVita’s board,” said Pam Arway, independent chair of the DaVita Inc. Board of…
NextGen Healthcare Reports Fiscal 2024 First Quarter Results
NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced its operating results for the fiscal first quarter ending June 30, 2023. Fiscal 2024 First Quarter Highlights “We are pleased to report solid top…
NextGen Healthcare Chosen by Kymera Independent Physicians to Expand Access to Critical Hematology and Oncology Care in Rural Areas
NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced Kymera Independent Physicians multi-specialty group selected NextGen® Enterprise EHR – a powerful, all-encompassing electronic health record to expand access to care, while increasing clinical productivity, enriching patient experience, and…